Summary
Boston Scientific Corporation (BSX) filed an 8-K on April 20, 2011, primarily to report its first-quarter 2011 financial results and a significant goodwill impairment charge. The company announced its Q1 2011 financial performance, details of which are provided in an accompanying press release. Investors should note the substantial non-cash goodwill impairment charge related to its U.S. Cardiac Rhythm Management (CRM) reporting unit. This charge is estimated to be between $650 million and $800 million, with a preliminary figure of $723 million. The impairment was triggered by updated market information indicating a reduction in the estimated size of the U.S. CRM market, leading to lower projected results for this segment. Importantly, the company stated that this impairment charge will not impact its existing debt covenants.
Key Highlights
- 1Boston Scientific announced its financial results for the first quarter ended March 31, 2011.
- 2The company recorded a significant goodwill impairment charge related to its U.S. Cardiac Rhythm Management (CRM) reporting unit.
- 3The estimated goodwill impairment charge is between $650 million and $800 million, with a preliminary write-down of $723 million.
- 4The impairment was driven by updated market information indicating a reduced market size for U.S. CRM.
- 5This impairment is a non-cash charge and does not impact the company's debt covenants.
- 6The detailed Q1 2011 financial results are available in the press release furnished as an exhibit to the 8-K.